Insights from the use of erythropoietin in experimental Chagas disease

Nobre, Ana Carolina de Castro; Pimentel, Carlos Fernando; Rêgo, George Magno Sousa do; Paludo, Giane Regina; Neto, G. B. Pereira; Castro, Márcio Botelho de; Nitz, Nadjar; Hecht, Markus; Dallago, Bruno Stéfano Lima; Hagström, Luciana

doi:10.1016/j.ijpddr.2022.05.005

Cited by 2 publications

(2 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of benznidazole, the result was slightly different, since the prevalent isotype was IgG2a with a predominance of a Th1-type immune response, which could be related to a reduction in parasitemia [ 32 ]. In addition, antibody production influences inflammatory cell infiltration in tissues; therefore, it has been observed that the inflammatory process, mainly in cardiac tissue, is directly related to the levels of IgG [ 33 ]. This finding agrees with our work, in which nitazoxanide-treated mice were found to have slightly higher organ indices and inflammation scores than benznidazole-treated mice, with the latter showing lower IgG1 levels and higher IgG2 levels, indicating better infection control through a balanced Th1/Th2 immune response as the disease progressed.…”

Section: Discussionmentioning

confidence: 99%

Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model

et al. 2023

View full text Add to dashboard Cite

Chagas disease (ChD), caused by Trypanosoma cruzi, is the most serious parasitosis in the western hemisphere. Benznidazole and nifurtimox, the only two trypanocidal drugs, are expensive, difficult to obtain, and have severe side effects. Nitazoxanide has shown to be effective against protozoa, bacteria, and viruses. This study aimed to evaluate the nitazoxanide efficacy against the Mexican T. cruzi Ninoa strain in mice. Infected animals were orally treated for 30 days with nitazoxanide (100 mg/kg) or benznidazole (10 mg/kg). The clinical, immunological, and histopathological conditions of the mice were evaluated. Nitazoxanide- or benznidazole-treated mice had longer survival and less parasitemia than those without treatment. Antibody production in the nitazoxanide-treated mice was of the IgG1-type and not of the IgG2-type as in the benznidazole-treated mice. Nitazoxanide-treated mice had significantly high IFN-γ levels compared to the other infected groups. Serious histological damage could be prevented with nitazoxanide treatment compared to without treatment. In conclusion, nitazoxanide decreased parasitemia levels, indirectly induced the production of IgG antibodies, and partially prevented histopathological damage; however, it did not show therapeutic superiority compared to benznidazole in any of the evaluated aspects. Therefore, the repositioning of nitazoxanide as an alternative treatment against ChD could be considered, since it did not trigger adverse effects that worsened the pathological condition of the infected mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In an effort to improve the effectiveness of BNZ, it has been tested in combination with other drugs [ 33 , 34 ] or it has been administered in different presentations, such as micro- and nanoparticles [ 35 , 36 ]; in addition, other molecules have been used as alternative treatments [ 37 , 38 , 39 ]. The prevailing need to find a targeted treatment for CD that is effective in the acute and chronic stages, mainly against the cardiac presentation, and that does not have serious side effects, led to the study of NTZ and EOW as treatment in the canine model.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Nitazoxanide and Electrolyzed Oxiding Water in Treating Chagas Disease in a Canine Model

Rodríguez-Morales,

Mendoza-Téllez,

Morales-Salinas

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Chagas disease (CD) is caused by the protozoan Trypanosoma cruzi, and affects seven million people in Latin America. Side effects and the limited efficacy of current treatment have led to new drug research. The objective of this work was to evaluate the effectiveness of nitazoxanide (NTZ) and electrolyzed oxidizing water (EOW) in a canine model of experimental CD. Náhuatl dogs were infected with the T. cruzi H8 strain and NTZ- or EOW-treated orally for 10 days. Seronegativity was shown at 12 months post-infection (mpi) in the NTZ-, EOW-, and benznidazole (BNZ)-treated groups. The NTZ and BNZ groups had high levels of IFN-γ, TNF-α, IL-6, IL-12B, and IL-1β at 1.5 mpi and low levels of IL-10. Electrocardiographic studies showed alterations from 3 mpi and worsening at 12 mpi; NTZ treatment produced fewer cardiac pathomorphological changes compared to EOW, similar to BNZ treatment. There was no cardiomegaly in any group. In conclusion, although NTZ and EOW did not prevent changes in cardiac conductivity, they were able to avoid the severity of heart damage in the chronic phase of CD. NTZ induced a favorable proinflammatory immune response after infection, being a better option than EOW as a possible treatment for CD after BNZ.

show abstract

Insights from the use of erythropoietin in experimental Chagas disease

Cited by 2 publications

References 118 publications

Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model

Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model

Effectiveness of Nitazoxanide and Electrolyzed Oxiding Water in Treating Chagas Disease in a Canine Model

Contact Info

Product

Resources

About